No headlines found.
No press releases found.
No news found.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Cellyan Biotechnology Co. - Class A trades on the NASDAQ stock market under the symbol HKPD.
As of April 24, 2026, HKPD stock price climbed to $0.64 with 10,190 million shares trading.
HKPD has a beta of 1.22, meaning it tends to be more sensitive to market movements. HKPD has a correlation of 0.03 to the broad based SPY ETF.
HKPD has a market cap of $15.14 million. This is considered a Sub-Micro Cap stock.
HKPD has underperformed the market in the last year with a return of -35.2%, while the SPY ETF gained +34.7%. In the last 3 month period, HKPD fell short of the market, returning -22.3%, while SPY returned +3.8%. However, in the most recent 2 weeks HKPD has outperformed the stock market by returning +15.7%, while SPY returned +5.0%.
HKPD support price is $.57 and resistance is $.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HKPD shares will trade within this expected range on the day.
